Beijing South Region Oncology Hospital, a leading institution dedicated to oncology for over a decade, has made significant strides in the diagnosis and treatment of hepatocellular carcinoma (HCC) liver cancer. The hospital’s commitment to multidisciplinary collaboration and its innovative treatment strategies have positioned it at the forefront of cancer care in China.
**A Decade of Excellence in Tumor Treatment**
For the past ten years, Beijing South Region Oncology Hospital has established itself as a pioneer in oncology, specializing in comprehensive tumor diagnosis and treatment. The hospital advocates a multidisciplinary approach by integrating medical resources from various departments, thereby ensuring that patients receive personalized and effective care. This model has proven highly successful in managing complex cancers, including HCC liver cancer, which remains a major health challenge globally and particularly in China.
**Understanding HCC Liver Cancer**
Hepatocellular carcinoma is the most common type of primary liver cancer, accounting for approximately 75% of all liver cancer cases worldwide. It often develops in the context of chronic liver diseases such as hepatitis B and C infections, cirrhosis, and fatty liver disease. Early diagnosis is critical for improving survival rates; however, HCC is often detected at advanced stages due to subtle symptoms in its initial phases.
**Multidisciplinary Cooperation: A Cornerstone of Effective Management**
The hallmark of Beijing South Region Oncology Hospital’s treatment philosophy is its commitment to multidisciplinary cooperation. Recognizing the complexity of HCC liver cancer, the hospital has established specialized cooperation groups dedicated to single diseases, including a focused team for liver cancer.
These teams bring together experts from hepatology, oncology, radiology, surgery, pathology, interventional medicine, and other relevant fields. This collaborative framework allows for comprehensive patient evaluations, crafting individualized treatment plans that address the unique characteristics of each case.
Dr. Li Wei, Head of the Liver Cancer Treatment Group, explains, “HCC is a multifactorial disease, and its management requires close collaboration among various specialists. Our multidisciplinary groups enable us to combine expertise to improve early diagnosis, optimize treatment options, and monitor patients closely throughout their treatment journey.”
**Innovative Diagnostic and Treatment Techniques**
The hospital employs state-of-the-art diagnostic tools such as enhanced imaging technologies, including contrast-enhanced ultrasound, CT scans, MRI, and advanced biopsy techniques to accurately identify and stage liver tumors. In addition, molecular and genetic analyses are conducted to better understand tumor biology and identify potential therapeutic targets.
On the treatment front, Beijing South Region Oncology Hospital offers a wide array of options tailored to disease stage and patient health, including surgical resection, liver transplantation, local ablation therapies, transarterial chemoembolization (TACE), targeted drug therapy, and immunotherapy.
For early-stage patients, surgical resection or liver transplantation remain the gold standard with curative intent. When surgery is not feasible, minimally invasive treatments such as radiofrequency ablation and microwave ablation provide effective alternatives with reduced recovery times.
For patients with intermediate or advanced disease, TACE is widely applied to control tumor growth by delivering chemotherapy directly to the tumor and blocking its blood supply. Moreover, the hospital integrates targeted therapies such as sorafenib and lenvatinib, as well as immunotherapies that harness the patient’s immune system to fight cancer cells.
**Patient-Centered Care and Follow-Up**
The hospital’s approach extends beyond clinical treatment to encompass comprehensive patient care, including psychological support, nutritional guidance, and rehabilitation services. Given the chronic nature of liver disease and the risk of recurrence in HCC, long-term follow-up care is emphasized to monitor patient health and detect any signs of tumor return early.
Ms. Zhang Mei, a liver cancer survivor treated at the hospital, shares her experience: “From diagnosis through treatment and recovery, the multidisciplinary team was with me every step of the way. Their coordinated care helped me regain confidence and hope.”
**Looking Ahead: Research and Training**
Continuing its commitment to advancing liver cancer care, Beijing South Region Oncology Hospital actively participates in clinical research and trials aimed at developing new diagnostic methods and treatment protocols. The hospital also serves as a training center, educating medical professionals on multidisciplinary oncology care to promote best practices nationwide.
Dr. Li adds, “Our goal is to establish a model of comprehensive, multidisciplinary liver cancer care that can be replicated across the country, ultimately improving outcomes for all patients.”
**Conclusion**
Beijing South Region Oncology Hospital’s decade-long dedication to multidisciplinary cooperation has transformed the landscape of HCC liver cancer treatment. By integrating diverse medical specialties and leveraging advanced technologies, the hospital provides patients with personalized, effective care that enhances survival and quality of life. As the hospital continues to innovate and share expertise, it remains a beacon of hope for liver cancer patients across China and beyond.